Medical Director, MRD Oncology Clinical Development

labcorp; United States; Remote; USD 320,000 - 340,000; Full time

Job summary

Labcorp Oncology is seeking a Medical Director, Clinical Development for the MRD Portfolio in solid tumors. The role leads clinical development, designs evidence-generation programs, and collaborates with cross-functional teams to establish MRD testing in oncology care.

The successful candidate is a board-certified Medical Oncologist with extensive experience in clinical development, evidence generation, and external scientific engagement across multiple tumor types.

Qualifications

• Board-certified Medical Oncologist with solid tumor expertise.
• 5+ years of post-fellowship clinical experience in oncology.
• 8+ years designing, leading, or supporting clinical studies (prospective/retrospective).
• 5+ years cross-functional collaboration with operations, biostatistics, regulatory, medical affairs, and market access.

Responsibilities

• Lead MRD clinical development across solid tumors, guiding evidence generation and clinical adoption.
• Define clinical evidence requirements, populations, and validation strategies for MRD testing.
• Collaborate with R&D, product, and market access to guide assay development and biomarkers.
• Engage external investigators and key opinion leaders to advance portfolio strategy and adoption.

Skills

Medical Oncology

MRD/ctDNA

Clinical Development

Evidence Generation

Cross-functional Leadership

Publications

Regulatory Submissions

KOL Engagement

Education

MD/DO

Board Certification in Medical Oncology

Job description

Labcorp Oncology is seeking a Medical Director, Clinical Development for the MRD Portfolio in solid tumors. The role leads clinical development, designs evidence-generation programs, and collaborates with cross-functional teams to establish MRD testing in oncology care.

The successful candidate is a board-certified Medical Oncologist with extensive experience in clinical development, evidence generation, and external scientific engagement across multiple tumor types.